Dyrenium

Nephrotic Syndrome, Edema, Swollen feet or ankles + 8 more
Treatment
20 Active Studies for Dyrenium

What is Dyrenium

TriamtereneThe Generic name of this drug
Treatment SummaryTriamterene is a medication used to treat high blood pressure. It helps the body excrete more sodium and water while preventing the loss of potassium in the kidneys. This drug can cause an increase in potassium levels, which can be dangerous, and it can also make the skin more sensitive to sunlight. Triamterene was first approved by the FDA in 1964. It is used on its own or combined with hydrochlorothiazide to treat edema or hypertension.
Maxzideis the brand name
image of different drug pills on a surface
Dyrenium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Maxzide
Triamterene
1988
188

Effectiveness

How Dyrenium Affects PatientsTriamterene is a medication used to lower blood pressure and reduce swelling caused by fluid build-up. It works mainly in the kidneys, blocking the reabsorption of sodium and reducing the excretion of potassium. Too much potassium in the body can cause heart problems, so it is important to monitor your potassium levels when taking triamterene. It may also increase the effectiveness of hydrochlorothiazide, another drug used to lower blood pressure. Triamterene does not impact calcium levels in the body.
How Dyrenium works in the bodyTriamterene blocks the channels in your kidneys that normally let sodium and other ions through. By doing this, it increases the amount of sodium leaving your body and brings down the amount of potassium and other ions lost during urination. Triamterene is similar to another drug called amiloride, but it also increases the amount of magnesium you excrete in your urine.

When to interrupt dosage

The measure of Dyrenium is reliant upon the diagnosed ailment, including Cirrhosis, Hypokalemia and Edema. The amount of dosage is contingent upon the technique of delivery (e.g. Capsule or Tablet - Oral) outlined in the table beneath.
Condition
Dosage
Administration
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Congestive Heart Failure
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Thiazides
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Hypokalemia
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Nephrotic Syndrome
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Swollen feet or ankles
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Hypertensive disease
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Diuretics
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral
Cirrhosis
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral

Warnings

Dyrenium Contraindications
Condition
Risk Level
Notes
Renal Insufficiency, Chronic
Do Not Combine
Hyperkalemia
Do Not Combine
Pulse Frequency
Do Not Combine
Anuria
Do Not Combine
Liver diseases
Do Not Combine
There are 20 known major drug interactions with Dyrenium.
Common Dyrenium Drug Interactions
Drug Name
Risk Level
Description
Cyclosporine
Major
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Neomycin.
Tacrolimus
Major
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.
Tenofovir
Major
Triamterene may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Triamterene may increase the nephrotoxic activities of Tenofovir alafenamide.
Dyrenium Toxicity & Overdose RiskTaking too much triamterene can lead to nausea, vomiting, stomach cramps, weakness, and low blood pressure. This is because of electrolyte imbalances like high potassium levels. To treat an overdose, vomiting and stomach lavage should be done and the electrolyte and fluid balance should be monitored. Dialysis may also help remove the drug from the body. In mice, triamterene was linked to liver tumors, but this was not found to be dose-dependent. No mutagenic or chromosomal changes have been seen in studies. It is not recommended to take triamterene during pregnancy
image of a doctor in a lab doing drug, clinical research

Dyrenium Novel Uses: Which Conditions Have a Clinical Trial Featuring Dyrenium?

138 active studies are underway to assess the potential of Dyrenium in providing relief for Cirrhosis, Hypokalemia and Nephrotic Syndrome.
Condition
Clinical Trials
Trial Phases
Cirrhosis
52 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Edema
7 Actively Recruiting
Phase 4, Phase 2, Not Applicable, Phase 3
Diuretics
0 Actively Recruiting
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Edema
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Edema
0 Actively Recruiting
Hypokalemia
0 Actively Recruiting
Thiazides
0 Actively Recruiting
Nephrotic Syndrome
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3

Dyrenium Reviews: What are patients saying about Dyrenium?

4Patient Review
7/1/2009
Dyrenium for High Blood Pressure
I've developed leg cramps, indigestion, and a raw stomach since using this medicine one week ago.
3.7Patient Review
2/13/2009
Dyrenium for Low Amount of Potassium in the Blood
These cramps were really awful. I couldn't stand or walk without excruciating pain in my legs.
3Patient Review
2/3/2010
Dyrenium for High Blood Pressure
After taking just one pill of this medication, I started having cramps in my legs, calves, feet, and hands.
2Patient Review
6/22/2008
Dyrenium for High Blood Pressure
The side effects of this medication were so bad that I had to go to the ER, and no one even realized it was from the meds!
2Patient Review
5/2/2009
Dyrenium for Visible Water Retention
I experienced some side effects while taking this medication, such as dizziness and a rapid heart rate. However, it did successfully reduce fluid retention for me. I stopped taking it due to the intensity of the side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dyrenium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking triamterene?

"Abdominal or stomach pain, feeling very agitated, black or tarry-looking stool, blood in the urine or stool, clay-colored stool, cloudy urine, seizures, less urine than usual."

Answered by AI

Does Dyrenium lower potassium?

"The medication Triamterene (Dyrenium) can increase the levels of potassium in your body."

Answered by AI

What is the purpose of triamterene?

"Triamterene is a diuretic that helps to treat edema by reducing the amount of fluid retained in the body. It is typically used in conjunction with other medications to treat conditions such as heart and liver disease."

Answered by AI

What is Dyrenium used for?

"This medication is used to decrease swelling that is caused by conditions such as cancer, congestive heart failure, liver disease, and kidney disease. This effect can help your kidneys work better and lessen symptoms such as trouble breathing and swelling in your ankles, feet, hands, or belly."

Answered by AI

Clinical Trials for Dyrenium

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

AI-Enabled Identification for Fatty Liver Disease

18+
All Sexes
Los Angeles, CA
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical Center (+3 Sites)
Have you considered Dyrenium clinical trials? We made a collection of clinical trials featuring Dyrenium, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Image of Cleveland Clinic Main Campus in Cleveland, United States.

Metabolic Surgery and TIPS for Liver Cirrhosis

18 - 70
All Sexes
Cleveland, OH
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.
Phase 4
Recruiting
Cleveland Clinic Main CampusSobia Laique, MD
Image of NewYork-Presbyterian/Weill Cornell Medical Center in New York, United States.

Melatonin for Liver Cirrhosis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.
Recruiting
Has No Placebo
NewYork-Presbyterian/Weill Cornell Medical CenterAdam Buckholz, MD MS
Have you considered Dyrenium clinical trials? We made a collection of clinical trials featuring Dyrenium, we think they might fit your search criteria.Go to Trials
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Image of Research Site in Calgary, Canada.

Baxdrostat for Hyperaldosteronism

18+
All Sexes
Calgary, Canada
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks to based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and approximately 12 countries.
Phase 3
Recruiting
Research Site (+22 Sites)AstraZeneca
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Dyrenium clinical trials? We made a collection of clinical trials featuring Dyrenium, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security